Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xingbaiji Formula with Chemo-Immunotherapy in Advanced NSCLC
NCT06848426Not yet recruiting
- Sponsor
- Jiangxi Provincial People's Hospital
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Xingbaiji Formula in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jiangxi Provincial People's Hospital. Primary endpoint: Objective Response Rate at 6 months. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
Xingbaiji Formula
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06848426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848426.